EKF Diagnostics Holdings PLC Purchase of Own Shares & Buyback Prog. Completion (8753H)
11 4월 2022 - 3:01PM
UK Regulatory
TIDMEKF
RNS Number : 8753H
EKF Diagnostics Holdings PLC
11 April 2022
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Purchase of Own Shares
& Completion of Share Buyback Programme
EKF, the AIM-listed global diagnostics business, announces that
it has purchased a further 200,000 of its ordinary shares at a
price of 40 pence per share. The ordinary shares purchased will be
held in treasury.
This transaction marks the successful conclusion of the share
buyback programme as set out in the announcement on 29 March 2022.
Under that programme, a total of 9,000,000 ordinary shares were
purchased at an average cost of 43.29 pence per share. Buying back
this amount of ordinary shares at current levels more than offsets
the dilutive effect of the new ordinary shares issued in 2021.
Aggregated information related to the most recent Purchase of
Own Shares
Date of purchase 8 April 2022
Number of ordinary shares purchased 200,000
-------------
Highest price paid per share 40
-------------
Lowest price paid per share 40
-------------
Volume weighted average price
paid 40
-------------
Transaction details
In accordance with Article 5(1)(b) of Regulation (EU) No
596/2014 (the Market Abuse Regulation) (which forms part of
domestic UK law pursuant to the European Union (Withdrawal) Act
2018) , a detailed breakdown of individual trades is available
below:
Number of ordinary Transaction price Time of transaction Trading venue
shares purchased (GBp)
200,000 40 08:24:00 AIMX
------------------ -------------------- --------------
Total voting rights
Following the purchase, the Company's total issued share capital
will consist of 463,930,564 ordinary shares of 1 pence each
("Ordinary Shares") each carrying one voting right, of which
9,000,000 Ordinary Shares are held in treasury. Therefore, the
total number of Ordinary Shares carrying voting rights will be
454,930,564. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Mike Salter, CEO Tel: +44 (0)29 2071 0570
Marc Davies, CFO
Singer Capital Markets (Nominated Adviser & Tel: +44 (0)20 7496 3000
Joint Broker)
Aubrey Powell / George Tzimas / Tom
Salvesen
Investec Bank plc (Joint Broker) Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams / Ben
Farrow
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44 (0)7584
391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading global diagnostics business with custom
manufacturing facilities across sites in the US, UK and Europe for
a variety of life science products. EKF is focussed on the
following areas:
Point-of-Care Providing a portfolio of Point-of-Care analysers and
consumables, particularly for use in the area of Hematology
and Diabetes, for use in hospital and research laboratories,
doctor's offices, blood banks and for in-field anaemia
screening programmes. EKF has an estimated 80,000
hemoglobin, hematocrit, HbA1c, glucose and lactate
analysers in regular use across more than 100 countries.
Central Laboratory Clinical chemistry, Small lab analysers, Centrifuges
Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor , Glycates
Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin
Life Sciences Enzyme fermentation, Custom products and Bulk fermentation
Contract Manufacturing Bulk formulation, Sample collection kits, Private
labelling, Molecular and forensic kits
Laboratory Services In September 2021, EKF completed the acquisition of
Advanced Diagnostic Laboratory LLC ("ADL Health")
, a Texas based testing laboratory certified under
the Clinical Laboratory Improvement Amendments ("CLIA")
for high complexity testing. The laboratory provides
testing for a variety of clinical, forensic and microbiological
sample types using a range of analytical techniques.
This acquisition positions EKF as a leading 'one stop'
provider of diagnostic products and services from
sample collection to results.
In May 2021, EKF announced its strategy for delivering growth to
2024 and beyond, and continuing to deliver shareholder value. The
strategy for growth can be summarised as:
-- continuing innovation in products and services in Point-of-Care,
Central Laboratory and Life Sciences leveraging new and existing
routes to market and relationships;
-- investment in expanded production and kitting capabilities to offer
a suite of diagnostic Contract Manufacturing solutions to third
party businesses;
-- expansion of CLIA Laboratories Testing offering, building on the
acquired capabilities in ADL Health; and
-- identify complementary earnings-enhancing acquisitions with key
strategic value.
EKF will also continue to generate enhanced shareholder value
through:
-- a progressive dividend policy; and
-- its agreement with Mount Sinai Innovation Partners ("MSIP"), which
allows us advanced access to innovative commercial opportunities
and where we can build on the ongoing successes of Renalytix plc,
Verici Dx plc and Trellus Health plc.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
POSIMMFTMTABBFT
(END) Dow Jones Newswires
April 11, 2022 02:01 ET (06:01 GMT)
EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
